All In Biotech

NDA 202379 · Janssen Biotech

Zytiga

Abiraterone Acetate · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Aug 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Apr 28, 2011

Approved uses

5

Original approval plus efficacy supplements

Registered trials

415

71 Phase 3, 75 recruiting

FAERS reports

33,780

23,026 serious, 7,312 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 28, 2025.

ZYTIGA is indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )

Mechanism: Abiraterone acetate (ZYTIGA) is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by 17α-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase activity. DHEA and androstenedione are androgens and...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ZYTIGA · ABIRATERONE ACETATE 500MG · TABLET, ORAL · Prescription · TE AB
  • ZYTIGA · ABIRATERONE ACETATE 250MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Abiraterone" as an intervention, any sponsor and status, largest first.

All 415 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death5,397
  • fatigue2,061
  • drug ineffective1,687
  • prostatic specific antigen increased1,669
  • therapy cessation1,483
  • hot flush1,048
  • asthenia997
  • hospitalisation955
  • nausea841
  • off label use840
  • disease progression830
  • diarrhoea794

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201014
2011266
2012683
2013933
20141,262
20152,561
20162,219
20173,408
20184,566
20194,791
20203,784
20211,979
20222,889
20231,514
20241,081
20251,168
2026662

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zytiga (Abiraterone Acetate)

2024 spending

$22.0M

Beneficiaries

315

2,104 claims

Per beneficiary

$69,997

$143.48 per unit

View as table
YearSpending
2020$347,156,246
2021$127,825,786
2022$54,212,441
2023$33,242,472
2024$22,048,927

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 603 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.